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ABSTRACT 
 
Olanzapine is one of the most commonly used antipsychotic drugs in treatment of 
schizophrenia and bipolar disorder. The interindividual variability in pharmacokinetics of 
olanzapine is extensive, with a 10-20-fold difference in serum concentration despite 
equivalent dosing. The aim of this thesis was to identify and evaluate factors that influence 
the pharmacokinetics of olanzapine, and thereby provide knowledge that can be applied in 
order to individualize treatment with olanzapine. 
Therapeutic drug monitoring samples from patients treated with olanzapine were used 
as data material in all four studies of the thesis. The serum concentration of olanzapine and 
metabolites were quantified with liquid chromatography-mass spectrometry (LC-MS) 
analyses. Overall, cigarette smoking, age and gender were shown to be significant 
determinants of olanzapine variability. Non-smokers generally obtained a two-fold higher 
dose-adjusted serum concentration (C/D ratio) compared to smokers. Age and gender were 
also shown to be significant determinants of olanzapine C/D ratio, but the numerical effects of 
these factors were less than those mentioned above. Furthermore, it was shown that 
comedication with the antiepileptic drugs valproic acid and carbamazepine substantially 
affected C/D ratio of olanzapine. The estimated reductions were approximately 30% and 50%, 
respectively. Concurrent use of ethinyl-estradiol containing contraceptives and a mutation in 
the gene encoding uridine diphosphate glycosyl transferase 1A4 (UGT1A4) did not affect 
serum concentration of olanzapine significantly, but both were shown to have significant 
impact on metabolic pathways of olanzapine. 
In conclusion, the present thesis reveals that cigarette smoking, age, gender and 
comedication with valproic acid or carbamazepine are significant factors which contribute to 
the variability in pharmacokinetics of olanzapine. Summarized, a female, non-smoking patient 
60 years receiving olanzapine monotherapy, would on average obtain a more than 3-fold 
higher C/D ratio compared to a male, smoking patient <60 years comedicated with valproic 
acid or carbamazepine. To improve the therapeutic effect and reduce the risk of side effects, 
these factors should be considered as a basis for individualized dosing of olanzapine in 
clinical practice.  
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1 INTRODUCTION 
1.1 Schizophrenia and bipolar disorder 
Schizophrenia is considered the costliest mental illness in terms of both human suffering and 
social expenditure. The lifetime prevalence is estimated to be 0.3-0.7%.1 Schizophrenia is a 
developmental syndrome deriving from multiple genetic and environmental factors.2 
Although schizophrenia is often viewed as a single disease, it is now recognized that the 
diagnostic category probably comprises a group of disorders with heterogeneous etiology.3 
Patients with schizophrenia experience positive symptoms, including hallucinations and 
delusions, thought disorders, and negative symptoms like social withdrawal.4 
 
Numerous long term prognostic studies in schizophrenic patients have shown that the clinical 
outcome is good for 20-50% of the patients, with different definitions like total remission, no 
readmission and symptomatic recovery. A similar proportion of the patients are characterized 
by a poor outcome (15-45%), with definitions like severe chronic social- or intellectual 
deficit, moderate to severe symptoms at follow up or chronic psychotic symptoms.4 This 
heterogeneity of outcome is mainly unexplained.5 Some clinical predictors of poor outcome 
have been identified, including early onset, long period of untreated psychosis, prominent 
negative symptoms and poor premorbid adjustment.6 Early response to treatment may also be 
a predictor of good outcome.7;8 Though some biochemical predictors for metabolic side 
effects of antipsychotic medication have been identified, no clinically relevant biochemical 
markers for the outcome of schizophrenia are known.8  
 
Bipolar disorder has been described as a cyclical illness, with manic and/or depressive 
episodes interspaced with normal euthymic periods. Further evidence suggest that patients 
with bipolar disorder experience a more subtle chronic course than initially thought, 
characterized by residual symptoms, emotional dysregulation, sleep disturbances, cognitive 
impairment, and increased risk of psychiatric and medical comorbidity.9 Bipolar disorder is 
grouped into several categories based on the severity and cycling of the symptoms (e.g. 
bipolar I, bipolar II, rapid cycling and mixed states). Severe episodes of mania might involve 
psychosis and are often accompanied by periods of depression. Bipolar disorder shares some 
of the symptoms and biology with schizophrenia suggesting some shared etiological 
mechanisms.10 
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Antipsychotic drugs are effective in treatment of schizophrenia and bipolar disorder, and have 
been available for sixty years. They have been demonstrated to be important in prevention of 
relapse in schizophrenic patients.11 Since the discovery of chlorpromazine in 1952, more than 
30 antipsychotic drugs have been marketed. Traditionally the antipsychotic drugs have been 
divided into the first generation (typical) and second generation (atypical) agents. The first 
generation agents are characterized by good clinical effect against the positive symptoms, but 
poor response against negative symptoms. Moreover, their use has been limited by severe 
extrapyramidal side effects such as spasms, motor restlessness and involuntary movements. In 
comparison, the second generation antipsychotics better address negative symptoms of 
schizophrenia, and cause little extrapyramidal side effects. However, these latter are 
accompanied by metabolic side effects (weight gain, lipid- and glucose disturbances), which 
are seldom for first generation agents. 
 
Common for antipsychotics is the ability to block dopamine 2 (D2) receptors, which explains 
the effect towards positive symptoms via reduction of mesolimbic hyperactivity in 
dopaminergic transmission.12 However, as the negative symptoms of schizophrenia are related 
to decreased dopamine activity in the mesocortical dopamine pathway, this represents a major 
challenge for pharmacologic treatment of schizophrenia. Ideally, agents used in treatment of 
schizophrenia should exert opposite effects on the same receptor system in different parts of 
the brain. The antipsychotic drug aripiprazole was developed to address this challenge by 
acting as a partial dopamine agonist, instead of being D2-antagonists like the other 
antipsychotics. Besides the effect on D2-receptors, second generation antipsychotics 
antagonize serotonin 5HT2A-receptors.  
1.2 Olanzapine 
Olanzapine is a second generation antipsychotic approved for use in treatment of schizophrenia 
and bipolar disorder. It was first approved for clinical use in the European Union in 1996, and 
has become one of the most commonly used antipsychotic drugs worldwide.  Olanzapine was 
the most prescribed antipsychotic drug in Norway in 2010, both in terms of defined daily doses 
(DDD) and number of users.13 WHO defines DDD of olanzapine to 10 mg.14 According  
to data from the Norwegian Prescription Database, it was dispensed a total of  
4 336 324 DDDs to 15799 of unique olanzapine users in Norway in 2010. These numbers 
relates to olanzapine dispensed directly to patients through Norwegian pharmacies, and do not 
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include sale to hospitals and other institutions.13 In Norway, olanzapine is now marketed in 
four different formulations, i.e. ordinary tablets, orally disintegrating tablets, solution for 
injection and depot injection.15 Indications include acute psychosis in patients with 
schizophrenia or manic episode, long-term treatment of schizophrenia and prevention of manic 
episodes in bipolar patients. In the US market olanzapine is also approved in set combinations 
with the antidepressant fluoxetine, for use in treatment-resistant depression and bipolar I 
depression.16   
 
Olanzapine improves negative and positive symptoms of schizophrenia.17 It is considered one 
of the most effective antipsychotic drugs, with lower rates of discontinuation and greater 
reduction in symptoms compared to both first- and other second-generation antipsychotic 
agents.18;19 The favourable effects, however, are accompanied by more frequent side effects 
than certain other antipsychotics.11 Weight gain, dyslipidemia, type II diabetes and heart 
disease are all serious adverse effects associated with olanzapine, which have limited its use in 
some patient groups, e.g. the elderly. 
 
 
Figure 1 Chemical structure of olanzapine. 
(2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine) 
 
The molecule is a thienobenzodiazepine (Figure 1), with structural and functional similarities 
to clozapine. Olanzapine is well absorbed after administration of ordinary tablets, with 
maximum concentration reached after 5-8 hours and unaffected by food intake. Olanzapine is 
highly bound to plasma proteins (approx. 93%), primary to albumin and to a lesser extent 
alfa1-acid glycoprotein.20 On average, the elimination half life and clearance of olanzapine are 
reported to be 33 h and 26.1 L/h respectively. Bioavailability is 0.8 and the hepatic extraction 
ratio is 0.4.21;22 Metabolism of olanzapine is covered in section 1.4.4. 
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1.3 Drug metabolism 
The human body has a number of detoxification and transport systems to aid excretion of 
foreign substances (xenobiotics), including drugs. Psychoactive drugs, including olanzapine, 
are lipophilic compounds. This is a necessity in order to pass the blood brain barrier and exert 
pharmacodynamic effect in the central nervous system (CNS). This also means that most 
psychoactive drugs need to be metabolized to more water-soluble molecules prior to excretion 
via urine or bile.  
 
Drug metabolism is traditionally divided into “phase I” and “phase II” reactions. Phase I 
reactions involve processes which modify the primary molecular structure by reactions such 
as reduction, oxidation or hydrolysis. Some phase I metabolites are sufficiently polar to be 
directly excreted in urine or bile, but phase I reactions may also facilitate further metabolism 
(phase II) of the molecules. The cytochrome P450 (CYP) superfamily is regarded as the most 
important enzyme system in phase I metabolism of drugs, but other families such as the 
flavin-containing monooxygenase (FMO) system are also of relevance.   
 
Phase II metabolism involves conjugation of the primary molecules to so called co-substrates, 
which are polar, small-molecular compounds like glucuronic acid, amino acids, sulphate or 
glutathione. Phase II enzymes often conjugate these latter compounds to functional groups on 
the molecule resulting from phase I metabolism, or like in the case of olanzapine - via direct 
glucuronidation of a functional group on the parent molecule. While phase I metabolites may 
display relevant pharmacological activity, phase II reactions often result in inactive 
molecules. The superfamily of uridine diphosphate glycosyltranferase (UGT) enzymes is one 
of the most important for phase II metabolism of many drugs. 
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1.3.1 Cytochrome P450 
The CYP enzymes are involved in oxidative metabolism of many clinically used drugs. More 
than 50 different human CYP enzymes are identified,23 but CYP1A2, CYP2C9, CYP2C19, 
CYP2D6 and CYP3A are regarded the most important ones in the metabolism of 
xenobiotics.24 Some CYP enzymes also metabolize endogenous compounds, e.g. fatty acids, 
hormones and cholesterol, but those mentioned above are usually of minor relevance in 
endogenous metabolism.25  
 
CYP enzymes are located in the endoplasmatic reticulum of cells that provide external tissue 
barriers, e.g. enterocytes, hepatocytes, dermatocytes and lung epithelial cells, in order to limit 
systemic exposure of foreign substances. In addition, CYP enzymes are expressed to some 
extent in the brain, where they may locally contribute to metabolism of endogenous substrates 
and drugs.26   
 
The individual variability in CYP enzyme phenotype is extensive due to genetic and 
environmental factors.27;28 Most of the CYP enzymes are prone to induction and inhibition, 
making CYP-related drug-drug interactions (DDI) a relevant issue regarding clinical safety 
and effect of many drugs. Details and examples are listed in section 1.5.  
1.3.2 Uridine diphosphate glycosyltranferase 
The superfamiliy of uridine diphosphate (UDP) glycosyltranferase (UGT) enzymes is 
important in conjugative (phase II) metabolism of drugs, but also play a crucial role in 
metabolism of many endogenous substrates.29 UGT metabolism leads to increased water 
solubility of the substrate and therefore aids excretion through the kidneys. Glucuronidation 
will usually inactivate substrates, by increasing size and polarity of the molecule, and hamper 
binding to drug receptors. The UGT1A and UGT2B subfamilies, the most important ones in 
drug metabolism, acts by adding UDP glucuronic acid to an electron-rich (e.g. nitrogen, 
oxygen, carboxyl or sulphur) part of a substrate. 
 
There are identified 15 human enzymes within the UGT1A and UGT2B subfamilies,30 they 
are expressed mainly in liver, but also found in the gastrointestinal tract and kidney.31 
Enzymes within these families catalyze the conjugation of glucuronic acid (Figure 2) to the  
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respective substrates. This is in contrast to UGT3 and UGT8, which catalyze the attachment 
derivates from other sugar residues, e.g. galactose and N-acetylglucosamine.32 Despite 
conjugation of different co-substrates, most authors still refer to UGT as UDP 
glucuronosyltransferases.29   
 
 
 
 
Figure 2 Structure of glucuronic acid  
 
 
Individual differences in metabolism via UGTs could be of importance both with respect to 
disease risk and drug response. Regarding the former, inherent deficiency in the function of 
UGT1A is associated with conditions like the Gilbert and Crigler-Najjar syndromes, which 
causes toxic hyperbilirubinemia.33;34 Newborns and infants lack UGT capacity,35 and might 
develop lethal accumulation of UGT substrates. This is exemplified by the “gray baby 
syndrome” that might develop in children after administration of UGT substrate 
chloramphenicol.  
 
In contrast to the CYP system, substrate specificity is lower in the UGT system. Several 
UGTs catalyze conjugation of the same substrates, especially in O-glucuronidation.  N-
glucuronidation is an exception to this, with UGT1A4 and the less studied UGT2B10,36 being 
specialized in performing N-glucuronidation. Some of these metabolites are rather specific to 
humans (e.g. N-glucuronides from amines, amides and aromatic N-heterocycles).37 This 
complicates in vivo extrapolation of in vitro results from animal models.38 UGT1A4 are 
considered the most important subfamily in relation to psychotropic drug, catalyzing N-
glucuronidation of antidepressants, antipsychotics and antiepileptics.38  
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1.3.3 Flavin-containing monooxygenase 
The flavin-containing monooxygenases (FMOs) are mainly known to metabolize exogenous 
substances like toxins, pesticides and drugs.39 There are identified five functional isoforms of 
FMO (FMO1-5).40 Expression of FMO1, FMO2 and FMO4 is limited in human beings, and 
FMO3 is believed to be the most prominent in drug metabolism.40 FMO enzymes are 
expressed in kidney (FMO1 and 4), lung (FMO2 and 4) liver (FMO 3, 4 and 5) and intestine 
(FMO4).41 In an average human liver, the FMO3 level is approximately 65% compared to the 
widely expressed CYP3A4.42 FMO3 therefore has the potential to be an important enzyme in 
the metabolism of drugs. Still, there has been limited focus on FMO3 and other FMO 
enzymes compared to other drug-metabolizing enzymes, such as CYP and UGT enzymes. 
However, some in vivo studies have demonstrated that substances like some H2-receptor 
antagonists (ranitidine and cimetidine), NSAIDS (sulindac and benzydamine) and nicotine are 
substrates of FMO3.43 Little is known about the potential induction or inhibition of FMO3, 
but a spontaneous ‘back-reduction’ of FMO3-mediated metabolites to the parent drug has 
been described.44 This phenomenon might have underestimated the impact of FMO3 as an 
enzyme of relevance in the context of drug metabolism and potential drug interactions.  
 
1.3.4 Metabolism of olanzapine 
The most important eliminating mechanism for olanzapine is metabolism via multiple 
pathways. Summarized, the most relevant enzymes for metabolism of olanzapine are 
uridinediphosphate (UDP) glycosyltransferase 1A4 (UGT1A4), cytochrome P450 1A2 
(CYP1A2) and flavin-containing monooxygenase 3 (FMO3).21 These mediate formation 10-
N-glucuronide olanzapine, N-desmethyl olanzapine and N-oxide olanzapine, respectively 
(Figure 3).20;45;46 Other enzymes are also involved in the metabolism of olanzapine (e.g. 
CYP2D6 and CYP3A), but appear to play minor roles in the overall clearance.45   
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Figure 3 Pathways of olanzapine metabolism in humans (based on 20;45;47) 
 
1.4 Pharmacokinetic variability 
1.4.1 Genetic polymorphism 
Genetically determined differences in function of drug-metabolizing enzymes are generally 
important factors for interindividual variability in pharmacokinetics. The phenotypical 
consequences of genetic variants include defective, reduced or increased expression or 
activity of the protein of relevance.  
 
Within the field of pharmacogenetics, most attention has been paid to genetic polymorphisms 
of drug-metabolizing enzymes, in particular CYP enzymes, where the clinical relevance of 
genetic variability is best documented for CYP2C9, CYP2C19 and CYP2D6.48-51  Examples 
include 10-fold higher AUC and more adverse drug reactions of atomoxetine in CYP2D6 
poor metabolizers compared to extensive metabolizers.52 The antiplatelet drug clopidogrel is a 
prodrug activated by CYP2C19, and carriers of reduced function CYP2C19 alleles treated 
with this drug are shown to have more major adverse cardiovascular events compared to 
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extensive metabolizers.53 Genetic polymorphisms also exist for other CYP enzymes, for 
example CYP1A2,54 but pharmacogenetic variability has so far appeared to be of clinical 
relevance mostly within the CYP2 family. Genetic testing of CYP2D6, CYP2C19 and 
CYP2C9 is a valuable tool for predicting dosing of many drugs that are substrates of these 
enzymes. Algorithms have been published to individualize drug doses based on the respective 
genotypes,43;55-57 but it seems to be a way to go before the potential benefit of genotyping is 
exploited in clinical practice.58 
 
Regarding UGT enzymes, genetic polymorphism with relevant functional consequences has 
been described for UGT1A4. An example is the UGT1A4 142T>G variant allele 
(UGT1A4*3), encoding an amino acid substitution (L48V), which has been reported to be of 
relevance for the pharmacokinetics of clozapine and lamotrigine.59;60 A pilot study indicated 
that UGT1A4*3 impacts olanzapine metabolism in humans as well,61 but a limitation of the 
studies performed so far is the absence of homozygous *3 carriers.60-63 A recent study also 
proves that differences in other UGT enzymes can be crucial for the disposition of drugs. A 
substance under development for respiratory diseases, MK-7246, displayed 25 fold higher 
AUC in homozygous carriers of UGT2B17*2 compared to carriers of the wild type.64 New 
discoveries are being made, but genetic variation of UGTs are complicated by processes 
beyond genetic polymorphism, i.e. variation due to epigenetic factors and splicing.65 This 
calls for more information regarding genetic and environmental variation of UGTs. 
 
Although poorly investigated, genetic variability might also be an important determinant for 
interindividual differences in FMO3-mediated metabolism. The expression of FMO3 is shown 
to vary more than 10-fold in an adult liver, and this variability might be associated with 
genetic factors.66 FMO3 mutations have been linked to clinical response of olanzapine in one 
study,67 but studies published on the pharmacokinetics of olanzapine in relation FMO3 
genetics are so far lacking. 
1.4.2 Non-genetic factors 
 
Drug-drug interactions 
In a clinical pharmacological context, drug-drug interactions (DDIs) represent one of the most 
important non-genetic factors behind individual pharmacokinetic variability. There are several 
pharmacokinetic DDI mechanisms, but inhibition or induction of drug-metabolizing enzymes 
 17
is generally considered as most relevant. Some drugs act as competitive inhibitors, while 
others act more ‘mechanistically’ by enzyme inactivation (reversible or irreversible). In 
general, all kind of enzyme inhibition has rapid onset, but the duration of inhibition depends 
on the mechanism. Inhibition of drug metabolism usually leads to increased serum levels of 
an active parent compound, however, the opposite might be the case for prodrugs. The 
pharmacokinetic sensitivity of enzyme inhibition will largely depend on the complexity of 
pathways involved in elimination of the substrate.  
 
Up-regulation of enzyme levels is the mechanism behind enzyme induction. Induction could 
be viewed as a response to increase the ‘xenobiotic defence’ following prolonged exposure of 
foreign substances. An inducer acts by stimulating binding of nuclear receptors and thereby 
increases transcription of genes encoding the respective enzymes. Induction is usually 
achieved during a time period of days to weeks. Many inducers act rather unspecifically (e.g. 
carbamazepine) by simultaneously up-regulating a number of enzymes involved in drug 
metabolism.68;69 The activity of CYP1A2, involved in olanzapine metabolism, could be 
induced or inhibited by a number of substances (see Table 1 for examples).70  
Table 1 Examples of substrates, inducers and inhibitors of CYP1A2 (based on Zhou et al.70) 
SUBSTRATES INDUCERS INHIBITORS 
Caffeine Carbamazepine Ciprofloxacin 
Clozapine Cruciferous vegetables Contraceptives (estrogens)  
Duloxetine Cigarette smoke Fluvoxamine 
Melatonin Grilled/smoked meat/food Rofecoxib 
Olanzapine Rifampicin  
Theophylline   
Tizanidine   
 
There are described several sources to variability in UGT1A4, including genetic 
polymorphism and interactions with endogenous and exogenous substances. Reports have 
been published on genetic variants in UGT1A4 and the effect of these, but with conflicting 
evidence and possibly also substrate specific effects.60;63;71;72 Some inducers are reported for 
UGT-enzymes, i.e. smoking, carbamazepine, alcohol, but the effects are mostly small and 
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inconsistent.73 Good probe substances and specific inducers/inhibitors of the various UGT 
isoforms are essential, but are complicated by the fact that several of the UGTs overlap in 
regard to metabolism of substrates. Table 2 provides examples of UGT1A4 substrates, 
inducers and inhibitors. 
 
Table 2 Examples of substrates, inducers and inhibitors of UGT1A4  
Based on Kaivosaari et al., Kiang et al. and Chen et al.38;74;75 
 
SUBSTRATES INDUCERS INHIBITORS 
Amitriptyline Carbamazepine Bilirubin 
Asenapine Smoking Valproic acid 
Chlorpromazine Estradiol  
Clozapine   
Imipramine   
Irinotecan   
Lamotrigine   
Olanzapine   
Progestins   
Promethazine   
Lifestyle and dietary factors  
Not only drugs are able to inhibit or regulate the transcription of enzymes – other xenobiotics, 
endogenous substances (hormones), pollutants (smoke) and dietary factors can also mediate 
these processes. Poly-aromatic hydrocarbons (PAH) are examples of substances that trigger 
up-regulation/induction of metabolism. PAHs belong to a class of substances that are often 
carcinogenic, teratogenic and mutagenic. Humans are exposed to PAHs through different 
sources, e.g. cigarette smoke, burned- or grilled food. PAHs are lipophilic ring structures that 
act in human cells by binding to the aromatic hydrocarbon receptor (AhR), which will cause 
up-regulation of enzymes (e.g. CYP1A). Activation of other nuclear receptors like 
constitutive androstane receptor (CAR) and pregnane X receptor (PXR) are also causes of 
induction.76 A classic example of dietary factors causing enzyme inhibition is grapefruit juice, 
but other food and herbal products are also reported to affect metabolizing enzyme e.g. the 
inducer hypericum/St John’s wort.77;78 Furthermore, infection, inflammation and cancer are 
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examples of disease states that also affect enzymes.79 Increased knowledge of all these factors 
is important, but controlling or estimating the effects of all these factors in the clinic is 
impossible. Although systemic concentrations do not necessarily correlate well with the 
concentration and pharmacodynamic effects of a certain drug, measuring the concentrations 
of drugs in blood, provides valuable information about pharmacokinetic variability of drugs.    
1.5 Therapeutic drug monitoring 
Therapeutic drug monitoring (TDM) has been available for several decades as a tool for 
quality assurance and individualization of drug treatment. TDM is today more or less 
implemented in treatment monitoring of immunosuppressants, anti-infective agents (HIV and 
antimicrobials), anti-cancer agents, psychoactive agents, anticoagulants and antiepileptics.80-82 
With regard to psychoactive drugs, TDM is important because few other objective biological 
effect markers exist.  
 
Older AEDs, tricyclic antidepressants and lithium have a well-documented concentration-
effect relationship, a so-called therapeutic window.80;83 The evidence for a concentration-
effect relationship is not that extensive for newer antidepressants and antipsychotics, although 
many of these also have curvilinear concentration relationships of clinical- and side effects.84 
In addition to being a tool for dose individualization, TDM may also aid the detection of 
adherence problems, pharmacokinetic DDIs and other risk factors related to drug use. The 
concept of TDM “Nouveau”, a term introduced by Bengtsson in 2004,85 state that the patients 
should be their own controls in sequence serum concentration measurements. The suggested 
strategy is to measure drug concentration when the response is good, obtaining a ‘therapeutic’ 
target concentration for the individual patient, applied as a reference for future monitoring. 
 
Pharmacogenetic testing has become an important part of TDM for detection of vulnerable 
patients, with the advantage of getting this information prior to initiating drug treatment. 
Genotype-based dose adjustments are relevant for many drugs55;86, and might reduce the use 
of “trial and error” in dosing of potent psychoactive drugs. Applying this into clinic could 
reduce the negative experience with drugs, aiding long term adherence and trust in patients.  
The US Food and Drug Administration (FDA) has in recent years increasingly been 
recommending pharmacogenetic tests prior to treatment with drugs like warfarin and 
clopidogrel.87  
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1.5.1 Therapeutic drug monitoring of olanzapine 
The AGNP-TDM consensus guidelines strongly recommend that serum concentration is 
monitored in patients using olanzapine, and suggests a therapeutic range of 20-80 ng/ml (64-
255 nmol/L).84 Serum concentrations have been related to clinical effect and side effects of 
olanzapine in several studies.88-92 For instance, a follow up analysis of serum concentration-
versus-clinical response data from the CATIE trial revealed a significantly higher 
discontinuation rate in patients with low serum concentrations of olanzapine, while patients 
with high serum concentrations had a significantly higher discontinuation rate due to side 
effects.19;93 There is an extensive interindividual variability in pharmacokinetics of 
olanzapine, and TDM studies have shown 25-fold differences in C/D ratio between patients.94-
96 A recent study in adolescents have also shown large intraindividual variability of 
olanzapine and metabolite levels, recommending repeated measurements to obtain more 
precise estimates of the pharmacokinetics in individual patients.97  
 
Discontinuation of treatment is an important reason of relapse in schizophrenic patient.98 The 
CATIE trial reported that 65-80% of the included patients discontinued antipsychotic 
treatment before 18 months of treatment. The median time to discontinuation was between 5-
8 weeks for the atypical antipsychotics.19  This represents one of the main problems of 
treatment with antipsychotics, and emphasizes the importance of TDM as a tool to avoid 
discontinuation of treatment.  
 
TDM is also of value for preventing serious side effects caused by changes in treatment or 
environment of patients. Studies have reported increased serum concentrations, serious side 
effects and intoxications of antipsychotics olanzapine and clozapine following smoking 
cessation.91;99 One might argue that these episodes could be prevented by changing the dosing 
based on experience and the clinic only. The typical concept of increasing doses to reach 
clinical effect, and stop when side effects occur, is still commonly used. This strategy does 
not take into account the “silent”, but potentially fatal, side effects of atypical antipsychotics. 
A study by Ray et al. showed increased risk of serious ventricular arrhythmias and sudden 
cardiac death in users of antipsychotics. The risk was shown to be dose-dependant,100 which 
necessarily means that serum concentration is of importance as well.  
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2 AIM OF THE THESIS  
 
The objective of this thesis was to identify and evaluate factors that contribute to the 
pharmacokinetic variability of olanzapine. Cigarette smoking (paper I), drug-drug interactions 
with oral contraceptives (paper II) and antiepileptic drugs (paper IV), and UGT1A4*3 
polymorphism (paper III) were investigated during this work. The studies also allowed 
exploration of the effect of age and gender on serum concentrations of olanzapine and 
metabolites. All studies were based on TDM data from Norwegian psychiatric patients. 
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3 SUMMARY OF RESULTS 
Paper I: The effect of variable cigarette consumption on the interaction with clozapine and 
olanzapine.
 
This paper describes the effect of variable cigarette smoking (i.e. cigarette ‘dose’) on serum 
concentrations of olanzapine and clozapine, in a group of 73 psychiatric patients (n=40 
olanzapine, n=33 clozapine). Dose-adjusted serum concentrations (C/D ratios) were on 
average twofold higher in non-smokers compared to cigarette smokers for olanzapine and 
clozapine. A total of 80% of the patients included were smokers, and these were divided into 
subgroups based on daily cigarettes (i.e. 1-6 [n=0], 7–12 [n=10], 13–19 [n=8], 20 [n=13]). 
There were no significant differences in C/D ratios between subgroups of smokers (p>0.7). 
None of the patients smoked 1-6 cigarettes daily, so we were not able to identify the lower 
threshold needed for the enzyme induction to occur. A daily consumption of 7-12 cigarettes 
did, however, seem to be sufficient to obtain maximum induction of the metabolism of 
olanzapine and clozapine. Studying the absolute serum concentrations, it appeared that non-
smokers were dosed too high, rather than cigarette smokers being dosed too low. This could 
possibly be explained by the fact that cigarette smokers have been overrepresented in this 
patient group and therefore predicted the therapeutic dose interval of olanzapine during drug 
development. Based on these findings, it seems reasonable that non-smokers should receive 
approximately half the dose of cigarette smokers when starting treatment with olanzapine or 
clozapine. Moreover, in a clinical setting, it seems adequate to classify patients into smokers 
and non-smokers when individualizing the dose based on smoking habits.  
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Paper II: The effect of ethinylestradiol-containing contraceptives on the serum 
concentration of olanzapine and N-desmethyl olanzapine. 
 
Ethinylestradiol-containing contraceptives (ECC) are known to inhibit CYP1A2 metabolism, 
but the potential interaction with the CYP1A2 substrate olanzapine had not previously been 
investigated. This study was carried out to explore the effect of ECC and progestogen-based 
contraceptives (PBC) on serum concentrations of olanzapine and the metabolite N-desmethyl 
olanzapine, which is formed via CYP1A2. Olanzapine-treated female patients aged 18-40 
years who used oral contraceptives were recruited from the TDM service at Diakonhjemmet 
Hospital along with a control group that did not use oral contraceptives. During a time period 
of 18 months, a questionnaire was by routine sent to the prescribing physician to collect 
information regarding contraceptive use and smoking habits among all female patients aged 
18-40. A total of 149 questionnaires valid for inclusion were returned, 10 out of these were 
from patients that used ECC and 10 from patients that used PBC. Although users of ECC had 
35-40% lower serum levels of N-desmethyl olanzapine compared to users of PBC (p=0.02) 
and the control group (p=0.01), the olanzapine levels were not significantly different between 
the three subgroups (p>0.9). The results of the study show that ECC inhibits CYP1A2-
mediated metabolism of olanzapine. However, this inhibition does not produce a clinically 
relevant interaction between ECC and olanzapine.  
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Paper III: UGT1A4*3 encodes significantly increased glucuronidation of olanzapine in 
patients on maintenance treatment and in recombinant systems 
This study investigated the effect of UGT1A4*3 on the metabolism of olanzapine in vitro and 
in vivo. A total of 558 psychiatric patients treated with olanzapine were genotyped. In patients 
that met the inclusion criteria (n=407), dose-adjusted serum concentration (C/D ratio) of 
olanzapine were compared between subgroups with different UGT1A4*3 genotype. 
Moreover, serum samples from 129 of these were available for reanalysis of 10-N-
glucuronide olanzapine, which is formed via UGT1A4. Frequencies of heterozygous and 
homozygous carriers of UGT1A4*3 were 16% and 1.8% respectively. Olanzapine C/D ratios 
were not significantly different between the UGT1A4*3 subgroups (p>0.4), but heterozygous 
and homozygous carriers of UGT1A4*3 had significantly higher levels of the 10-N-
glucuronide metabolite compared to the control group without the *3 mutation. The numerical 
differences were 1.4-fold (p=0.01) and 2.5 fold (p<0.001) higher levels of 10-N-glucuronide 
in heterozygous and homozygous carriers of UGT1A4*3, respectively, compared to patients 
homozygous for the wild-type. In line with these in vivo findings, microsomes expressing 
UGT1A4.3 exhibited significantly higher glucuronidation activity of olanzapine compared to 
microsomes expressing UGT1A4.1. Overall, the study shows that UGT1A4*3 encodes 
significantly higher glucuronidation activity of olanzapine, but this is not of clinical relevance 
for olanzapine treatment. 
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Paper 4: Valproic acid significantly lowers serum concentration of olanzapine – an 
interaction effect comparable to smoking. 
 
Olanzapine is frequently combined with mood stabilizing antiepileptic drugs (AEDs) in 
patients with bipolar disorder and schizophrenia. This study aimed to investigate the possible 
effect of AEDs on serum concentrations of olanzapine and three major metabolites. Patients 
were divided into subgroups based on coadministration of different AEDs, and a control 
group of patients that used olanzapine without concurrent AEDs. A total of 598 serum 
samples, from 430 patients, were included. Linear mixed models were used to investigate the 
effect of different AEDs, age, sex and cigarette smoking on dose-adjusted serum 
concentrations (C/D ratios) of olanzapine and metabolites. Significant effects on olanzapine 
C/D ratio were found in subgroups comedicated with valproic acid (-32%, n=166 samples, 
p<0.001), lamotrigine and valproic acid (-31%, n=12, p=0.003) and carbamazepine (-50%, 
n=8, p<0.001) compared to the control group. Age 60 (+35%, p<0.001), female gender 
(+11%, p=0.008) and cigarette smoking (-32%, p<0.001) were also highly significant 
predictors of olanzapine concentrations compared to patients younger than 60 years, males 
and non-smokers respectively. The interaction of valproic acid on olanzapine C/D ratio in the 
present study was comparable to the effect of cigarette smoking and should be considered 
clinically relevant. However, data on three major olanzapine metabolites did not explain the 
observed changes in olanzapine levels in valproic acid users, so the mechanism behind this 
interaction needs to be further investigated.  
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4 DISCUSSION 
 
This thesis has established that smoking habits, age, gender and comedication with certain 
mood-stabilizing antiepileptic drugs are important factors for interindividual variability in the 
pharmacokinetics of olanzapine. Together these factors explain approximately one third of the 
interindividual variability in dose-adjusted serum concentrations (C/D ratios) of olanzapine in 
TDM samples. By correcting for the factors shown to be significant determinants of 
olanzapine pharmacokinetics, it could be possible to predict a 3-4 fold individual difference in 
C/D ratio.  
 
The recommended therapeutic serum concentration range for olanzapine is 4-fold, i.e. 20-80 
ng/ml (64-255 nmol/L).84 By taking into account the factors evaluated as important 
determinants in the present thesis, it would be possible to individualize dosing of olanzapine 
to obtain safer and more effective treatment of many patients with schizophrenia or bipolar 
disorder. 
 
The UGT1A4*3 variant allele and comedication with ethinylestradiol-containing 
contraceptives were also possible factors of importance for interindividual variability in 
olanzapine pharmacokinetics. Although these factors significantly affected metabolic 
pathways of olanzapine, they were both shown not to be of importance for the variability of 
olanzapine C/D ratio in the present thesis.  
4.1 Impact of age, gender and weight on olanzapine serum concentration 
4.1.1 Age 
In study III and IV, patients older than 60 years had significantly higher C/D ratios of 
olanzapine compared to younger patients, i.e. about 20% and 35%, respectively. Age has 
earlier been reported to positively correlate with olanzapine levels, e.g. Weiss and colleagues 
found a 9.4% increase in olanzapine C/D ratio per decade of life, while Gex Fabry et al. 
reported a 27% higher olanzapine serum concentrations in patients 60 years.101;102 On the 
other hand, Skogh et al. did not find a relationship between age and olanzapine levels in a 
study based on TDM data.94;101;102 Thus, there has been some uncertainty regarding the impact 
of age on serum concentration of olanzapine. However, the consistent findings in the present 
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studies (paper III and IV), including a large number of patients, strongly indicate that 
advanced age is associated with increased risk of olanzapine serum concentrations above the 
suggested therapeutic range. Although the use of antipsychotics in certain groups of elderly 
patients have been questioned, i.e. FDA has warned about increased mortality in elderly 
patients with dementia,103 approximately 20% of the subjects included in study III and IV 
were older than 60 years. 
 
The increased C/D ratio of olanzapine in patients older than 60 years is probably due to an 
age-related decline in physiological parameters, such as cardiac output (blood flow), liver and 
kidney function, rather than reduced activities of metabolic enzymes. This is supported by 
parallel increases in parent drug and metabolites in study III and IV. Increased levels of both 
parent compound and the measured metabolites in the elderly are also in line with a recent 
TDM study of several antidepressants.104 This study concluded that patients above 65 years 
had 1.5-2-fold increased levels of antidepressants and metabolites.  
4.1.2 Gender 
The about 10-30% higher estimated C/D ratios of olanzapine in females than in males in study 
III and IV, is in line with earlier studies reporting 10-40% higher olanzapine concentrations in 
women compared to men.90;94;96;102;105 A gender difference in olanzapine pharmacokinetics 
may potentially reflect differences in drug-metabolizing phenotypes between males and 
females, a hypothesis which is actualized by the apparent inhibition of CYP1A2 
metabolism/activity by estrogens.106 However, study IV also reported higher levels of all 
metabolites in women, significant for 10-N-glucuronide olanzapine and N-oxide olanzapine. 
This might indicate that further elimination of the metabolites is also impaired.  
 
The effect of female gender on olanzapine serum concentration is in line with the earlier 
mentioned study of antidepressants, reporting 1.1-1.5-fold increased serum levels in women 
compared to men.104 Thus, one might speculate if the higher C/D ratio in women compared to 
men share some of the same mechanisms as for increased age, e.g. lower blood flow to drug-
eliminating organs. Moreover, gender differences in body composition may lead to higher 
volumes of distribution of lipophilic drugs in females than in males, which theoretically could 
result in higher steady-state trough levels of most psychotropic agents in female patients. 
Finally, gender differences in weight might also be of importance, but there is conflicting 
evidence regarding the impact of body weight on olanzapine levels.  
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4.1.3 Weight  
In Study I, information about the patients’ weight and height was also collected. We found no 
significant effects of these variables on olanzapine C/D ratio in this limited data material 
(n=40). In the subsequent studies (II-IV), height and weight were not included mainly because 
this kind of information is not available from the TDM requisition forms, which these latter 
studies were based on.  
 
Regarding other studies investigating the impact of body weight on olanzapine 
pharmacokinetics, Patel et al. found a 3-4% higher absolute concentrations of olanzapine for 
every 10 kg patient weight above 80 kg.105 On the contrary, in a study by Skogh et al., the 
body mass index (BMI) of the patients did not correlate with olanzapine C/D ratios. The latter 
observation is supported by data from the CATIE project where weight was not significantly 
associated with olanzapine clearance in a population pharmacokinetic model.96  
4.2 Impact of lifestyle and dietary factors on olanzapine serum 
concentration
4.2.1 Cigarette smoking 
Cigarette smokers have been reported to display about 40-65% lower serum concentrations of 
olanzapine compared to non-smokers.91;105;107-109 The impact of cigarette smoking on serum 
concentration of olanzapine was therefore evaluated in all four studies of the present thesis. 
Study I and III found significantly lower olanzapine levels in cigarette smokers, i.e 52% and 
55% lower C/D ratio compared to non-smokers, respectively. The differences in mean C/D 
ratios in smokers vs. non-smokers were somewhat lower in study II (-28%, data not presented 
in paper II) and study IV (-32%) probably because different patient populations were studied 
in II/IV and I/III.   
 
In study I, no significant difference in C/D ratios of olanzapine and clozapine was found 
between light (7-12 cigarettes per day) and heavy smokers (>20 cigarettes per day). However, 
in paper IV, we speculated that less smoking among bipolar than schizophrenic patients might 
have been the reason to the lower observed effect of smoking on olanzapine C/D ratio in 
study II and IV compared to study I and III. 
 
 29
A weakness of study I was the limited number of patients in each subgroup, as well as the 
statistical analyses, which were based on univariate tests without adjustment for covariates 
(age, gender etc.). Results from other studies investigating the impact of various number of 
cigarettes on the in vivo metabolism of CYP1A2 substrates (caffeine, clozapine or 
olanzapine) are inconsistent to some degree. In a study with male Chinese patients, olanzapine 
AUC was on average 45% lower in light smokers (1-5 cigarettes) and 65% lower in heavy 
smokers (more than 5 cigarettes) compared to non-smokers. Light smokers had significantly 
higher AUC compared to heavy smokers (p<0.05).107   Another study found a typical dose-
response relationship between the number of cigarettes smoked per day and caffeine 
clearance.110 In this study, including Caucasian subjects, subgroups of smokers had on 
average 1.22-fold (1-5 cigarettes daily; n=85), 1.47-fold (6-10 cigarettes; n=90), 1.66-fold 
(11-20 cigarettes; n=140) and 1.72-fold (>20 cigarettes, n=70) higher caffeine clearance 
compared to non-smokers (n=401).110 These data suggest that there is a dose effect of number 
of daily cigarettes, which support the lower observed effect of smoking on olanzapine C/D 
ratio in study II and IV than in studies I and III.  
 
4.2.2 Dietary factors 
Different types of food and drinks have been reported to influence CYP1A2 activity, e.g. 
roasted, burned or grilled organic foods,111;112 which may affect clearance of olanzapine. 
However, dietary factors are challenging to control for and information about dietary habits 
was not included in study I-IV. Thus, these are potential confounders in the present thesis, as 
smokers and non-smokers, or females and males, theoretically might have different dietary 
habits. Another aspect regarding dietary habits is that they may differ between various 
geographical populations. Along with genetic factors, potential differences in dietary habits 
need to be kept in mind when comparing studies in populations living in different parts of the 
world. This was illustrated by a study comparing CYP1A2 activity in Northern- and Southern 
European populations, i.e. Swedes and Serbs.113 This showed a significantly lower CYP1A2 
activity in the Serbs than in Swedes.113 The roasting process of coffee is believed to produce 
PAHs and thereby induce CYP1A2 in heavy coffee drinkers.114 Thus, a potential explanation 
for the differences in CYP1A2 activities observed between Swedes and Serbs, might be 
geographical variability in coffee consumption.  
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4.3 Effect of interacting drugs on olanzapine serum concentration 
Patients treated with olanzapine are commonly comedicated with psychotropic drugs, e.g. 
mood-stabilizing AEDs, antidepressants and other antipsychotics. The potential for drug-drug 
interactions (DDIs) are therefore relevant for olanzapine users.  
 
Recent findings suggest that at least 30-50% of bipolar and schizophrenic patients are treated 
with mood stabilizers.115-117 Lithium is considered first line treatment for bipolar patients, but 
use of lamotrigine and valproic acid has increased markedly at the expense of lithium and 
carbamazepine during the last 15 years.115 Mood stabilizers, in particular valproic acid, are 
also used in treatment of hostility and aggression in psychiatric patients.118 The increased 
clinical use of valproic acid and lamotrigine in psychiatry is probably due to a limited risk of 
side effects and potential for DDIs. However, findings in study IV show that use of valproic 
acid in psychiatric patients implies an interaction potential with olanzapine. In quantitative 
terms, the change in serum concentration of olanzapine during concurrent use of valproic acid 
is comparable to the interaction effect reported in combination with CYP1A2 inducers or 
inhibitors.119-122 
4.3.1 Valproic acid 
Valproic acid is metabolised by several UGT enzymes, including UGT2B7 and UGT1A4. 
123;124 Olanzapine and lamotrigine are also extensively metabolised by UGT1A4, but adding 
valproic acid to each of these drugs seems to have opposite effects on their respective serum 
concentrations. Comedication with valproic acid leads to a more than two-fold increase in 
lamotrigine levels,125;126 probably due to inhibition of UGT-mediated metabolism of the latter. 
On the other hand, decreased serum concentration of olanzapine has been observed in 
combination with valproic acid,127;128 which is in accordance with the significantly lower C/D 
ratio of olanzapine (-32%, p<0.001) reported in paper IV. However, the lowering of 
olanzapine was accompanied with a parallel and significant reduction in serum concentration 
of 10-N-glucuronide olanzapine (-26%, p<0.001). Thus, the latter actually suggests that 
valproic acid inhibits UGT1A4-mediated olanzapine metabolism, but that this mechanism is 
overruled by another interacting mechanism resulting in reduced serum concentration of 
olanzapine. 
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Regarding alternative and hitherto unknown interacting mechanism of valproic acid, it has 
been shown that valproic acid induces gene expression of MDR1 (ABCB1, P-glycoprotein) 
and CYP3A4.129 CYP3A4 has been shown to be able to metabolize olanzapine, but the 
relative impact of this enzyme is believed to minor for its overall clearance.45 Interestingly, 
however, a follow-up study of the CATIE trial significantly linked a SNP in CYP3A43 gene 
(rs472660) to the olanzapine clearance by explaining 5-10% of the interindividual variability 
(p=5.9e-7).93 Among the 25 tested SNPs, including several mutations in genes encoding 
enzymes involved in the metabolism of olanzapine, i.e. CYP1A2, CYP2D6, CYP3A and
FMO3, the mentioned CYP3A43 mutation was the only one that significantly predicted 
olanzapine clearance. This might suggest that CYP3A43, and potentially other isoforms 
within the CYP3A subfamily, is more important for olanzapine metabolism than earlier 
suggested.45 Olanzapine is also shown to be a substrate for MDR1,130 but interactions with 
MDR1 is believed only to cause minor changes in olanzapine serum levels.131 The potential 
induction of valproic acid on MDR1 activity is therefore unlikely to explain the reduction in 
olanzapine concentration during concurrent use. 
 
4.3.2 Oral contraceptives 
Oral contraceptives containing estrogen 
Oral contraceptives containing ethinyl estradiol (ECC) have been shown to increase serum 
concentration of the CYP1A2 probe tizanidine almost fourfold.132 Study II investigated the 
effect of ECC on olanzapine and N-desmethyl olanzapine concentrations. A significantly 
reduced formation of the CYP1A2-mediated metabolite N-desmethyl olanzapine was found, 
but no effect on parent olanzapine concentration was observed. While ethinyl estradiol is 
shown to inhibit CYP1A2,106 use of ethinyl estradiol also appears to induce glucuronidation 
activity, as reflected by reduced serum levels of the UGT substrate lamotrigine reported in 
multiple studies.75;133-135 This ‘dual mechanism’ could have been the reason why the decrease 
in N-desmethyl olanzapine concentration was not accompanied by increased concentration of 
olanzapine in females using ECC (paper II). However, the lack of effect of ECC on serum 
concentration of olanzapine could also reflect that CYP1A2 plays a limited role in its overall 
clearance.  
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Determination of the UGT-mediated metabolite 10-N-glucuronide olanzapine could have 
ruled out this hypothetical dual interaction mechanism of ECC on olanzapine. Unfortunately, 
reference substance of this metabolite was unavailable at the time when study II was 
conducted. In any case, study II revealed that combined use of ECC does not produce a 
clinically relevant interaction with olanzapine, but confirmed the CYP1A2-inhibitory activity 
of ethinyl estradiol.  
4.4 Effect of genetics on serum concentration of olanzapine  
UGT1A4 142T>G 
Several polymorphisms in the UGT1A4 gene have been described,136 but most attention so far 
has been paid to the 142T>G (L48V) polymorphism representing the UGT1A4*3 variant 
allele. There is conflicting evidence about the influence of UGT1A4*3 on the serum 
concentration of olanzapine. Studies by Ghotbi et al. and Mao et al. conclude that the serum 
concentration of olanzapine is significantly reduced in patients being heterozygous carriers of 
UGT1A4*3.61;62 However, this was not replicated in study III, including both heterozygous 
and homozygous UGT1A4*3 carriers. Nozawa et al. have also studied the impact of 
UGT1A4*3 on levels of olanzapine in Japanese patients.108 This study only included seven 
heterozygous carriers of UGT1A4*3, but in accordance with findings of paper III, olanzapine 
concentration was not significantly different in patients with UGT1A4*3 compared to patients 
without this variant allele.108  
 
Among the studies which have investigated the influence of UGT1A4*3 on serum 
concentration of olanzapine, the one presented in this thesis (paper III) is clearly the largest 
one (n=407). In study III, we managed to include 10 homozygous carriers of UGT1A4*3, 
whereas the other studies only included heterozygous carriers. The fact that no significant (or 
close to significant) reduction in olanzapine level was observed in patients homozygous for 
UGT1A4*3, strongly suggest that this variant allele is of no clinical relevance for the 
interindividual variability of olanzapine serum concentration.  
 
Despite that UGT1A4*3 appears to have no or limited impact on the serum concentration of 
olanzapine, it is little doubt that this mutation encodes increased glucuronidation of 
olanzapine. The substantially increased concentration of 10-N-glucuronide olanzapine 
observed in homozygous UGT1A4*3 carriers, was supported by a significantly higher 
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intrinsic clearance of olanzapine by microsomes expressing UGT1A4.3 (paper III). The in 
vitro part of study III, showed that the increased glucuronidation activity was due to a lower 
affinity constant (Km value) of olanzapine to UGT1A4.3 compared to UGT1A4.1. Overall, it 
is therefore possible that UGT1A4*3 could be an important factor for the interindividual 
pharmacokinetic variability of other UGT1A4 substrates than olanzapine. In addition to 
lamotrigine,60 a recent publication reported a significant impact of UGT1A4*3 on 
interindividual variability in serum concentrations of clozapine and N-desmethyl clozapine.59 
Other polymorphisms 
Several studies have investigated the effect of polymorphisms in various candidate genes on 
olanzapine concentrations, e.g. CYP1A2, CYP2D6, MDR1 (ABCB1) and FMO3. 
56;61;93;109;137;138 Laika et al. recently found the CYP1A2*1F variant haplotype to be of 
importance for olanzapine serum concentrations, with a 22% lower observed dose-adjusted 
serum concentrations in homozygous CYP1A2*1F carriers compared to non-carriers of this 
haplotype.92 However, the actual impact of CYP1A2*1F on CYP1A2 phenotype has been 
questioned,56;61;114;139 and was therefore not included in the present thesis. With respect to 
CYP2D6 genotype, previous studies by Carrillo et al. and Hägg et al. have concluded that 
variability in CYP2D6 metabolism is of no importance for olanzapine C/D ratio.109;137 Still, 
we decided to include CYP2D6 genotype as a covariate in study III, with the hypothesis that 
the relevance of CYP2D6 phenotype might depend on UGT1A4 genotype. However, CYP2D6 
genotype turned out to be of no significance for olanzapine C/D ratio regardless of UGT1A4 
genotype.    
 
Overall, most studies have failed to show an association between olanzapine pharmacokinetic 
and pharmacogenetic factors. An exception is CYP3A43,93 and further studies should 
concentrate on the role of CYP3A variant alleles as potential determinants of olanzapine 
serum concentration.  
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4.5 Methodological considerations 
 
There are methodological limitations in using TDM data as material for studying 
interindividual pharmacokinetic variability. A naturalistic setting involves less control with 
factors like adherence, comedication and environmental factors. The TDM requisition forms, 
which comprise the information source in studies III and IV, and partly study II, contain 
details regarding age, sex, comedication, smoking habits, daily dose, treatment duration, and 
time between last dose intake and sampling. In cases where information about the patient’s 
dose, smoking habits and sampling time lacked, the respective patients were excluded. 
However, regarding other factors, such as comedication, it was not possible to assure that all 
relevant details were actually provided.  
 
Variable conditions (temperature, light etc) with respect to storage and handling of serum 
samples between sampling at the physician’s office and reception at the laboratory also 
represent potential limitations of TDM studies. However, the methods used for analyses of 
drug and metabolite concentrations are fully validated and certified in accordance with the 
ISO15189 standard. It should be mentioned though, that the validation of the methods is 
based on spiked serum samples from healthy individuals not using any drugs or herbal 
remedies. This is in contrast to the included patients, who often use other drugs, which 
theoretically may affect mass-spectrometric detection in terms of signal suppression etc. 
 
The methodological limitations of TDM-based studies might be outweighed by inclusion of 
large data materials, as in the present thesis. Moreover, many view the application of 
naturalistic data as an advantage in projects aimed to identify significant determinants of 
individual variability. Due to the large degree of ‘noise’ in the data material, these studies 
decrease the risk of false positive findings (type 1 error).  
 
The use of TDM data for research purposes is important in identification of factors causing 
pharmacokinetic variability in naturalistic settings. Pharmacokinetic studies are often 
performed in healthy volunteers, and in limited number of patients. Without having to expose 
patients to the burden of participating in a prospective clinical study, it is possible to enrol 
large number of patients to TDM studies.  
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5 CONCLUSION 
 
The present work has determined the impact of several factors on the pharmacokinetic 
variability of olanzapine in psychiatric patients. Smoking habits, advanced age, female gender 
and comedication with valproic acid or carbamazepine were all found to be significantly 
associated with the dose-adjusted serum concentration of olanzapine. Together, these factors 
explained about one third of the overall variability. Thus, if they are taken into account as a 
basis for individualized dosing of olanzapine during treatment initiation, it will be possible to 
substantially reduce interpatient variability in olanzapine exposure. The potential clinical 
benefits of a more individualized dosing strategy, which implies that more patients will reach 
the target serum concentration range of olanzapine, are reduced frequencies of adverse effects 
and inadequate therapeutic response. This latter could be translated into better health for the 
patients and reduced health care costs for the society. 
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